✦ LIBER ✦

Cyclosporine in systemic sclerosis. results of a forty-eight–week open safety study in ten patients

✍ Scribed by Philip J. Clements; Peter A. Lachenbruch; Mildred Sterz; Gabriel Danovitch; Randall Hawkins; Andrew Ippoliti; Harold E. Paulus

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 804 KB
Volume: 36
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.1780360113

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Demonstration of safety in Alzheimer's p

Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study

✍ S. P. Kennelly; L. Abdullah; D. Paris; J. Parish; V. Mathura; M. Mullan; F. Craw 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

## Abstract ## Background Nilvadipine may lower rates of conversion from mild‐cognitive impairment to Alzheimer's disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypote

Radiologic evidence of disease modificat

Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. results of a 48-week multicenter study comparing low-dose cyclosporine with placebo

✍ ØYstein FØRre Md 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 815 KB

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB 👁 1 views

Erratum: Golimumab, a new human anti–tum

Erratum: Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ W. Rigby; H.-P. Tony; K. Oelke; B. Combe; A. Laster; C. A. von Muhlen; E. Fishel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ P. P. Tak; P. J. Mease; M. C. Genovese; J. Kremer; B. Haraoui; Y. Tanaka; C. O. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views